

Company Presentation

September 2019



Safe Harbor Statement and Risk Factors

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this presentation include statements about the company’s total addressable market and annual procedures; competitive companies, technologies and procedures; the company’s ability to implement its business model and strategic plan, including its commercialization, regulatory approval and reimbursement strategies; and implementation and completion of clinical trials and pivotal studies.

These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of the Lap-Band system, including the risk of default under our security agreement with Apollo Endosurgery entered into in connection with the transaction; the risk of default under our secured subordinated convertible debentures due June 28, 2019 that we issued in March 2019; our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system and LAP-BAND system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products.

These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed May 9, 2019. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

ReShape Lifesciences Vision Statement

To be the leading minimally invasive medical device company providing cutting-edge technologies for the treatment of obesity and metabolic disorders, which people want to be associated with and where the best employees want to work. As the preferred partner for bariatric professionals, we will be known for our first priority; helping those who are affected by obesity achieve a better quality of life.

New Story (Clean Slate)

- Strategically aligned portfolio – bariatric surgeons, laparoscopic procedure focus
- Reimbursed obesity product that reached over \$290M in annual gross revenue at its peak
- One year endpoint on ReShape Vest – Target of 2022 for CE Mark
- Experienced leadership with strong market knowledge

Recent Developments

- New Leadership With Strong Market Knowledge and Relationships
- Acquisition of LAP-BAND®
 - Global Regulatory Approval
 - Reimbursed by Major Insurance Providers
 - Existing Revenue With High Margins
- ReShape Vest Feasibility Study Complete
 - Excellent Weight Loss, Reduced Need for Patient Compliance
- ReShape Vest CE Mark Study Patient Enrollment, April 2020
 - Targeted Enrollment Completion in 2020
 - Endpoint for Approval At One (1) Year Follow-up
- Divestment of ReShape Balloon, potentially vBloc
- Implementation of ERP System
- Cap Table “Clean-up”
- Reduction of Costs, Including Headcount and Infrastructure

Experienced Management Team

BART BANDY – CHIEF EXECUTIVE OFFICER

- Health care executive with over 25 years of experience leading a variety of medical device companies, led original Lap-Band growth for 10 years
- Inamed/Allergan (Lap-Band product), Ethicon Endo-Surgery, Karl Storz Endoscopy, BroadSpot Imaging

SCOTT YOUNGSTROM – CHIEF FINANCIAL OFFICER

- Senior financial executive with over 30 years of strategic financial and operational experience in a variety of medical device companies
- Galil Medical (BTG), Anulex, Enpath Medical (Greatbatch), Compex Technologies (Donjoy), ACIST Medical (Bracco Group)

RAJ NIHALANI, MD – CHIEF TECHNOLOGY OFFICER AND BUSINESS DEVELOPMENT

- Medical device executive and physician entrepreneur with 20 + years of experience in small and large medtech companies
- Founder and CEO of BarioSurg (Vest), Onciomed, Medtronic, Endologix, Acufocus, Rox Medical, Mdnook

KEVIN CONDRIN – SENIOR VICE PRESIDENT, COMMERCIAL

- Over 20 years of global marketing, business development and sales experience in the medical device and bariatric industries
- Held various executive-level positions at USGI, Medtronic (Covidien), Karl Storz, Circon ACMI and USGI Medical

DOV GAL, BSc, DVM, MBA – VICE PRESIDENT, CLINICAL AND REGULATORY

- Over 25 years of executive leadership & consulting experience in medical device regulatory affairs, clinical research, compliance and reimbursement
- Clearflow, Edwards Lifesciences, Broncus Technologies, Medtronic (AVE), Florence Medical, Ultraguide

VIPUL SHAH – SENIOR VICE PRESIDENT, OPERATIONS AND R&D

- Operations and R&D Executive with over 19 years experience in variety of medical device companies
- Presbia Cooperatief U.A./Presbia PLC, Vistome, Coopervision, Ocular Sciences, Sunsoft

ReShape Lifesciences Milestones and Objectives



1

Drive Revenue & Clinical Outcomes

- Commercial organization focused on strategic markets for LAP-BAND®
- Drive revenue utilizing new long-term clinical data and patient marketing
- Solid customer service and patient follow up
- Build sales network OUS with experienced distributor network



2

Reimbursement

- LAP-BAND® is the only non-anatomy changing obesity product that is currently reimbursed
- Continue to support and promote reimbursement of LAP-BAND® in the U.S. and OUS (30 BMI, Adolescents)
- Continue to pursue ReShape Vest reimbursement strategy in Europe and U.S.



3

Grow Pipeline

- Complete CE Mark & US PMA trial for ReShape Vest
- Obtain outcomes/costs for the ReShape Vest similar to the sleeve gastrectomy for long-term profitable revenue
- Add complementary accessories and products



4

Sell vBloc Diabetes Portfolio

- Intellectual Property
- Grants, \$300k awarded → \$2M potential from NIH
- R&D resources

Corporate Objective to increase our share price and get back on NASDAQ listing

A medical technology company serving the growing worldwide obesity epidemic

Opportunity

\$1.64 billion/year
global bariatric surgical
device market, with CAGR of
5.7%¹



Market Solution

Safe, laparoscopic and
minimally invasive, anatomy
preserving solutions
with durable outcomes²



ReShape

Highly scalable portfolio of
proven and emerging
products to serve this
obesity market need

¹Global Forecast to 2023, published by MarketsandMarkets; <https://www.marketsandmarkets.com/Market-Reports/bariatric-surgery-device-market-173150134.html>

²The American Journal of Surgery 184 (2002) 51S-54S

Obesity: Epidemic Impact & Unmet Need



- More than 2.5 billion people are overweight or obese
 - 30% of the global population, 1 in 3 adults in the U.S.¹
- On current trajectory, 50% of the population will be overweight or obese by 2030¹
- Global economic impact of obesity is \$2 trillion or 2.8% of GDP¹
- Healthcare costs for severely or morbidly obese adults are 81% higher than for healthy weight adults²
- Obesity is responsible for 5% of deaths worldwide ²




Slightly over 1%
of obese
patients who
qualify have
surgery³

¹The State of Obesity: *Better Policies for a Healthier America*, 2016.

²McKinsey & Company Report (2014). Overcoming obesity: An initial economic analysis. Retrieved from https://www.mckinsey.com/~media/McKinsey/Business%20Functions/Economic%20Studies%20TEMP/Our%20Insights/How%20the%20world%20could%20better%20fight%20obesity/MGI_Overcoming_obesity_Full_report.ashx

³ASMB estimates.

ReShape's Opportunity for Today's Obesity Continuum (Global)




¹; World Health Organization. "Obesity and Overweight" <http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> 16 February 2018.

² OECD Analysis of National Health Survey Data. "Obesity Update 2017" www.oecd.org/health/obesity-update.htm.

Note: Obesity defined as Body Mass Index (BMI) $\geq 30\text{kg/m}^2$. OECD projections assume the BMI will continue to rise as a linear function of time.

ReShape's Opportunity for Today's Obesity Continuum (U.S.)




¹Agnihotri, et al. (2018) Real-World Safety and Efficacy of Fluid Filled Dual Intra-gastric Balloon for Weight Loss. *Clinical Gastroenterology and Hepatology Journal* (2018), doi 10.1016/j.cgh.2018.02.026.

²<http://www.healthdata.org/news-release/vast-majority-american-adults-are-overweight-or-obese-and-weight-growing-problem-among;>

³Health, United States, 2016, table 53 [PDF – 9.8 MB] Children and adolescents. May 3, 2017

⁴<https://asmbs.org/resources/obesity-in-America>

U.S. Obesity Procedure Mix (2015 – 2025E)*



*Published in June 2018 by the ASMBS. The ASMBS total bariatric procedure numbers are based on the best estimation from available data (BOLD, ACS/MBSAQIP, National Inpatient Sample Data and outpatient estimations; Global Bariatric Surgery Devices Market Analysis and Trends, Industry Forecast to 2025, Accuray Research; Canaccord Genuity Equity Research 2014

Gastric Stapling Procedures Are Not the Answer

There Is No Agreed Upon Standard of Care

Gastric Sleeve and Bypass procedures are invasive, anatomy changing and life altering
Long-term analysis of these procedures show complications & weight regain over long-term

Gastric Bypass Complications

As many as 1 out of every 10 gastric bypass patients do experience a non-life-threatening complication at some point ¹.

The most common complications include:

- Stomal Stenosis (narrowing of the opening from the stomach to your intestine) – About 5 out of every 100 patients
- Wound Infection – About 3 out of 100
- Bowel Obstruction – About 3 out 100
- Leak – About 2 out of 100
- Gastrointestinal bleeding – About 2 out of 100

¹ Dayer-Jankechova, A., Fournier, P., Allemann, P. et al. (2016) Complications After Laparoscopic Roux-en-Y Gastric Bypass in 1573 Consecutive Patients: Are There Predictors? OBES SURG (2016) 26: 12.

Gastric Sleeve Weight Regain

After two years, about 1 out of every 20 gastric sleeve patients have gained back some weight from their low point. At 5 years, the average gastric sleeve patient regains as much as 50% of the weight they lost ¹.

As with all bariatric surgeries, LSG is also associated with long-term weight regain. A recent systematic review has shown that the rate of weight regain could range from 5.7 % at two years to 75.6 % at six years².

¹ Golomb, Inbal & Ben David, Matan & Glass, Adi & Kolitz, Tamara & Keidar, Andrei. (2015). Long-term Metabolic Effects of Laparoscopic Sleeve Gastrectomy. JAMA surgery. 150. 10.1001/jamasurg.2015.2202.

² Lauti, M., Kularatna, M., Hill, A.G. et al. (2016) Weight Regain Following Sleeve Gastrectomy—a Systematic Review OBES SURG (2016) 26: 1326.

Surgical Staplers Under Review

FDA Opens Up on Surgical Stapler Problems

From January 1, 2011 to March 31, 2018, the FDA received over 41,000 individual medical device reports for surgical staplers and staples for internal use. Among them were reports of 366 deaths, more than 9,000 serious injuries, and more than 32,000 malfunctions.

Medpage Today, March 8, 2019

FDA Announces Sweeping Plan To Review Safety Of Surgical Staplers

The FDA acknowledged that “we are aware that many more device malfunction reports during this time frame” were submitted as “summary reports,” which go to the FDA but are not included in the public database known as MAUDE (the Manufacturer and User Facility Device Experience). Since the start of 2016, more than 1.1 million serious injury or malfunction reports went into the internal database instead of being disclosed in detail in MAUDE, which is widely used by doctors and researchers to track problems. **Kaiser Health News, March 8, 2019**

J&J’s Ethicon Issues Urgent Field Safety Notice Over Intraluminal Staplers

Johnson & Johnson subsidiary Ethicon has released an urgent field safety notice recalling select Intraluminal Staplers distributed in the UK and Ireland over issues with the devices that may affect their performance during surgeries. Earlier this month, Ethicon released a notice it filed in the Europe, the Middle East and Africa region warning of issues with intraluminal Staplers related to malformed staples and uncut washers.

Mass Device, April 25, 2019

FDA Proposes Reclassifying Surgical Staples for Internal Use

The agency proposes to reclassify the products from low risk to moderate risk medical devices with special controls. The agency said the reclassification is needed “based on new information”. **FDA News, April 26, 2019**

FDA General and Plastic Surgery Devices Panel Announcement of the Medical Devices Advisory Committee Meeting May 30-31, 2019

A recent number of the adverse events reported for surgical staplers for internal use prompted a proposed rule to up classify surgical staplers. In a Medical Devices Advisory Committee meeting, held on May 30, 2019, panel members unanimously agreed that surgical staplers for internal use should be reclassified as class II with special controls. **Executive Summary: <https://www.fda.gov/media/126211/download>**

ReShape Lifesciences' Minimally Invasive Portfolio

WHAT'S NOW




lap·band[®]
S Y S T E M



POPULAR ACCESSORIES
FOR BARIATRIC SURGERY

WHAT'S NEXT



ReShape
Vest[™]

NEXT-GEN TREATMENT FOR OBESITY
FOR INVESTIGATIONAL USE ONLY
IN CE CLINICAL TRIALS

¹ Dixon JB, Eaton LL, Curry T, et al. Health outcomes and Explant Rates after Laparoscopic Adjustable Gastric Banding: A Phase 4 Multicenter Study over 5 Years. Obesity, 2018. Jan 26(1) 45-52

² DeMaffia E, PadeV, Warthen M, et al. Baseline data from American Society for Metabolic and Bariatric Surgery – designated Bariatric Surgery Centers of Excellence using Bariatric Outcomes Longitudinal Database.

*ReShape Vest is for investigational use only and not approved for use.

LAP-BAND® Technology



- ReShape Acquires LAP-BAND® December 2018
- FDA approved
- Reimbursed in the U.S.
- High margin product

\$19.4 M

2018 Revenue

18% TWL (5 yrs.)¹
(n=383)

>860,000
Patients Implanted²

48.9 EWL* (20 yrs.)³
(n=7264)

22% TWL (20 yrs.)**
(n=35)

650+

Physicians Implanting

Low removal and
complication rates^{1,4}

*EWL: Excess Weight Loss, The Percentage of Weight Lost From The Difference of Beginning Body Weight and Ideal Body Weight

**TWL: Total Weight Loss, The Percentage of Weight Lost From The Total Beginning Weight of Patients

¹Dixon JB, Eaton LL, Curry T, et. al. "Health Outcomes and Explant Rates After Laparoscopic Adjustable Gastric Banding: A Phase 4, Multicenter Study over 5 years, Obesity (2018) 26, 45-52


²Data on file. ReShape Lifesciences Inc.

³O'Brien, Annemarie Hindle, Leah Brennan, Stewart Skinner, Paul Burton, et al. "Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-Analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding." Obesity Surgery. The Journal of Metabolic Surgery and Allied Care. Published online: 06 October 2018. <https://doi.org/10.1007/s11695-018-3525-0>

⁴DeMària E, Pate V, Warthen M, et al. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2010 Jul-Aug;6(4):347-55.

LAP-BAND® Value Add: Improved Comorbidities & Healthcare Cost Savings

COMORBIDITY RESOLUTION



Improved
 Resolved

¹Michaelson, et. al. Obesity (2013) 21:1148-1158

²Ray et. al. "Safety, Efficacy, and Durability of Laparoscopic Adjustable Gastric Banding in a Single Surgeon U.S. Community Practice." Surgery for Obesity and Related Diseases 7 (2011) 140-144

³O'Brien, Annemarie Hindle, Leah Brennan, Stewart Skinner, Paul Burton, et al. "Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-Analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding." Obesity Surgery. The Journal of Metabolic Surgery and Allied Care. Published online: 06 October 2018. <https://doi.org/10.1007/s11695-018-3525-0>

⁴Dixon et. al. "Marked Improvement in Asthma after Lap-Band Surgery for Morbid Obesity." Obesity Surgery, 9, 385-389

⁵Dixon et.al. "Health Outcomes of Severely Obese Type 2 Diabetic Subjects 1 Year After Laparoscopic Adjustable Gastric Banding." Diabetes Care 25:358-363, 2002

⁶Dixon et. al. "Sleep Disturbance and Obesity. Changes Following Surgically Induced Weight Loss." Arch Intern Med 2001:161:102-106

⁷Dixon et. al. "Gastroesophageal Reflux in Obesity: The Effect of Lap-Band Placement." Obesity Surgery, 9, 527-531

Inamed Introduction and Growth

<u>Year</u>	<u>Revenue</u>		<u>Growth</u>		<u>Due to:</u>	<u>Impact:</u>
	<u>(in million's)</u>	<u>\$\$ (million's)</u>	<u>Growth</u>			
1999	\$ 14.25	\$ 6.2	77%		Intl. Launch	Increased Global Sales by 77%
2000	\$ 15.85	\$ 1.6	11%		Intl. Subsidiary Growth	Increased Global Sales by 12%
2001	\$ 20.75	\$ 4.9	31%		Intl. Transition to Distributors	Increased Global Sales by 39%
2002	\$ 35.65	\$ 14.9	72%		FDA Approval	Increased US/AUS/LA Sales by 183%
2003	\$ 59.45	\$ 23.8	67%		U.S. Expansion	Increased US/AUS/LA Sales by 99%
2004	\$ 84.55	\$ 25.1	42%		U.S. Reimbursement	Increased US/AUS/LA Sales by 44%
2005	\$ 125.25	\$ 40.7	48%		U.S. Reimbursement & Local Marketing	Increased US/AUS/LA Sales by 59%
2006	\$ 166.55	\$ 41.3	33%		U.S. Reimbursement & Regional Marketing	Increased US/AUS/LA Sales by 43%
2007	\$ 239.15	\$ 72.6	44%		U.S. National Marketing Campaign	Increased US Sales by 54%

What Happened Post Inamed

- Allergan assumed full control in 2008 with \$296M in revenue
- Allergan divested product in 2013 to Apollo: \$110M purchase, \$60M revenue
- Reason: focus on larger product lines within their pharma expertise, challenges from other procedures

- Apollo assumed full control in 2013
- Apollo divested product in 2018, with minimal sales and marketing conducted (2 direct representatives in the US)
- Reason: focus on endoscopic suturing and balloon technologies

Lap-Band Integration and Sales Strategy

Integration: Agreements in Place

- Product Supply Agreement: protects against disruption in supply
- Transition Services Agreement: ensures seamless transition of policies and processes

United States: Stabilize Lap-Band Sales


- Field Representatives: Increase from 2 to 5 to support core surgeons
- Focus on customer support and follow-up
- Educate on actual clinical data
- Launched Co-op marketing campaigns
 - ✓ Focus on top U.S. surgeon customers
 - ✓ Partner with clinics in marketing efforts
 - ✓ Drive qualified LAP-BAND® leads to surgeons
- Launched Digital Marketing & Lead Management test markets

OUS: Sales Network within First 9 Months of 2019

- Focus on top customers in top five countries through distributors: Australia and four European countries represent majority of recent OUS revenue
- Mexico provides great opportunity from historical perspective, former #1 distributor OUS
- Revive many ignored and abandoned countries while divesting of non-essential markets
- Leverage ReShape Vest clinical results, and potential market opportunity

ReShape Vest Technology

ReShape
Vest™



- Currently investigational use
- EU clinical trial started March 2019
- Not anatomy altering
- Intended for morbidly obese needing rapid weight loss
- Acquired May 2017

35-50

Patient BMI Range

Wraps around stomach to restrict amount of food eaten; emulates standard of care weight loss surgery

85.5%

Excess Weight Loss (1 Year)¹

12 point drop
in BMI

15"
Waist Reduction¹

8 Patients Enrolled
CE Mark Study Initiated
Q2 / 2019
Results Imitating Pilot Study

One Year End Point
Post Enrollment for
CE Mark

¹Juan López-Corvalá MD, Fernando Guzmán-Cordero MD, Cleysa Hermsillo-Valdez MD, Janine Rosales-Landgrave MD, "Gastric Vest System: Initial Results of a Novel Restrictive Bariatric Procedure"

Intellectual Property



ReShape LAP-BAND®

- Comprehensive patent portfolio of U.S and Foreign patents related to LAP-BAND® technology
- 101 Total U.S. and Foreign patents and Applications
- 22 U.S Patents in seven families
- 54 Patents in European Countries
- 226 Total U.S. and Foreign Trademark and applications.



ReShape Vest

- Intellectual property for gastric restriction device to treat obesity
- 4 granted U.S. patents
- 4 granted foreign patents in China, Israel, Canada and Australia



Bioelectronic Medicine Utilizing Vagus Nerve

- Broad coverage for neuroregulation of vagus nerve/ bioelectronic systems and methods related to neuroblocking, neuromodulation, and neurostimulation technology
- Coverage of vagus nerve applications including obesity, bulimia, pancreatitis, heart rate regulation, glucose regulation
- 45 granted U.S. patents, additional pending
- 45 granted foreign patents in Australia, Europe, China and Japan, additional pending

ReShape Lifesciences Milestones and Objectives



1

Drive Revenue & Clinical Outcomes

- Commercial organization focused on strategic markets for LAP-BAND®
- Drive revenue utilizing new long-term clinical data and patient marketing
- Solid customer service and patient follow up
- Build sales network OUS with experienced distributor network



2

Reimbursement

- LAP-BAND® is the only non-anatomy changing obesity product that is currently reimbursed
- Continue to support and promote reimbursement of LAP-BAND® in the U.S. and OUS (30 BMI, Adolescents)
- Continue to pursue ReShape Vest reimbursement strategy in Europe and U.S.



3

Grow Pipeline

- Complete CE Mark & US PMA trial for ReShape Vest
- Obtain outcomes/costs for the ReShape Vest similar to the sleeve gastrectomy for long-term profitable revenue
- Add complementary accessories and products



4

Sell vBloc Diabetes Portfolio

- Intellectual Property
- Grants, \$300k awarded → \$2M potential from NIH
- R&D resources

Corporate Objective to increase our share price and get back on NASDAQ listing

YTD Revenue vs Plan, Prior Year & 2017

Region	Actual	Plan	Inc/(Dec)		Prior Year	Inc/(Dec)		Prior Year	Inc/(Dec)	
	Q1 2019	Q1 2019	\$\$	%	Q1 2018	\$\$	%	Q1 2017	\$\$	%
US	2,592,674	2,773,246	(180,572)	-6.51%	2,938,039	(345,365)	-11.75%	4,238,000	(1,299,961)	-30.67%
EMEA	474,000	-	474,000	#DIV/0!	1,520,501	(1,046,501)	-68.83%	1,729,000	(208,499)	-12.06%
APAC	-	-	-	#DIV/0!	630,765	(630,765)	-100.00%	1,031,000	(400,235)	-38.82%
LATAM	-	-	-	#DIV/0!	7,800	(7,800)	-100.00%	13,000	(5,200)	-40.00%
Canada	7,559	25,357	(17,798)	-70.19%	107,393	(99,834)	-92.96%	148,000	(40,607)	-27.44%
Totals	3,074,233	2,798,603	275,630	9.85%	5,204,497	(2,130,264)	-40.93%	7,159,000	(1,954,503)	-27.30%

Region	Q2 2019	Q2 2019	\$\$	%	Q2 2018	\$\$	%	Q2 2017	\$\$	%
	US	2,847,453	2,851,390	(3,937)	-0.14%	2,630,702	216,751	8.24%	4,910,000	(2,279,298)
EMEA	1,129,530	669,078	460,452	68.82%	1,413,912	(284,382)	-20.11%	1,752,000	(338,088)	-19.30%
APAC	420,941	608,687	(187,746)	-30.84%	592,364	(171,423)	-28.94%	750,000	(157,636)	-21.02%
LATAM	-	-	-	#DIV/0!	15,300	(15,300)	-100.00%	9,000	6,300	70.00%
Canada	16,788	75,377	(58,589)	-77.73%	70,497	(53,709)	-76.19%	124,000	(53,503)	-43.15%
Totals	4,414,712	4,204,532	210,180	5.00%	4,722,775	(308,063)	-6.52%	7,545,000	(2,822,225)	-37.41%

Region	YTD 2019	Plan 2019	\$\$	%	YTD 2018	\$\$	%	YTD 2017	\$\$	%
	US	5,440,127	5,624,636	(184,509)	-3.28%	5,568,741	(128,614)	-2.31%	9,148,000	(3,579,259)
EMEA	1,603,530	669,078	934,452	139.66%	2,934,412	(1,330,882)	-45.35%	3,481,000	(546,588)	-15.70%
APAC	420,941	608,687	(187,746)	-30.84%	1,223,129	(802,188)	-65.58%	1,781,000	(557,871)	-31.32%
LATAM	-	-	-	#DIV/0!	23,100	(23,100)	-100.00%	22,000	1,100	5.00%
Canada	24,347	100,734	(76,387)	-75.83%	177,890	(153,543)	-86.31%	272,000	(94,110)	-34.60%
Totals	7,488,945	7,003,135	485,810	6.94%	9,927,272	(2,438,327)	-24.56%	14,704,000	(4,776,728)	-32.49%



ReShape Lifesciences Inc. (OTCQB:RSL)
1001 Calle Amanecer
San Clemente, CA 92673

Barton P. Bandy
President, Chief Executive Officer
(949) 276-6020
bbandy@reshapelifesci.com

Scott P. Youngstrom
Sr. Vice President - Finance, Chief Financial Officer
(949) 276-6042
syoungstrom@reshapelifesci.com